DUBLIN and LOUISVILLE, Ky., Oct. 2, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, to explore new ideas and ways to improve the health and well-being of patients, members and their caregivers.
A main objective of the Allergan and Humana collaboration is to study key issues and obtain a more comprehensive understanding of opportunities for improvement in care delivery.
"In today's changing health care environment, it is important for various stakeholders in the healthcare system to come together to gain in-depth understanding of unmet needs and find solutions to improve patient outcomes," said Gavin Corcoran, MD, FACP, Chief Medical Officer, Allergan. "This partnership aligns with our goal of leveraging real world data to build evidence and conduct comparative effectiveness research in collaboration with health care systems to better understand unmet needs, the natural history of disease, and interventions that improve both outcomes and the quality of care delivered to patients."
"The partnership with Allergan reflects Humana's commitment to improving health outcomes while reducing costs," said William Fleming, Pharm. D., President of Humana Pharmacy Solutions. "Humana is always looking to collaborate where we see an opportunity to make it easier for people to engage the health care system and looks forward to focusing on these initiatives with Allergan."
Under the terms of the agreement, Allergan and Humana will initially focus on the following initiatives:
- Variety of Diseases – Improving health of patients with central nervous system conditions, including Alzheimer's disease, as well as glaucoma and other eye diseases with opportunities to expand into other therapeutic areas as the collaboration progresses.
- Patient/Caregiver Relationship – Obtain a clearer picture of the attributes associated with caregiver burden from the caregiver perspective, and how self-reported caregiver burden relates to healthcare-related utilization and costs.
- Interventional Research – Conduct research based on interventional practices and predictive analytics, with a focus on treatment adherence, to ensure patients obtain the right medications at the right time.
One of the collaboration's first projects focuses on Alzheimer's patients' caregiver burden. Unlike caregiving for many terminal illnesses, caregiving for Alzheimer's disease may persist for much longer given that patients with Alzheimer's disease can live for many years.
"Caregivers are vulnerable to health consequences as a result of the chronic stressors associated with caring for a person with Alzheimer's disease," said Roy Beveridge, MD, Humana's Chief Medical Officer. "By working together, Humana and Allergan can help close a gap in care by going beyond the patient and focus on how to better understand and support caregivers."
Caregiver burden in Alzheimer's disease tends to increase with the progression of disease and corresponding increase in severity. In addition, caregiver traits themselves may also be influential; e.g., distance from patient, caregiver self-esteem, financial status, and health status may affect the level of caregiver burden.
Humana provides a wide variety of resources on caregiving. For additional information, please contact https://www.humana.com/individual-and-family-support/caregivers/.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model—Growth Pharma. Allergan is focused on developing, manufacturing, and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines, and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, health care providers, and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com
Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company's strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people Humana serves across the country.
More information regarding Humana is available to investors via the Investor Relations page of the company's web site at www.humana.com, including copies of:
- Annual reports to stockholders
- Securities and Exchange Commission filings
- Most recent investor conference presentations
- Quarterly earnings news releases
- Replays of most recent earnings release conference calls
- Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
- Corporate Governance information
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA and other regulatory approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (such periodic public filings having been filed under the "Allergan plc" or "Actavis plc" names) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Humana Corporate Communications
SOURCE Allergan plc